艾滋病抗病毒治疗新药绥美凯上市了吗

Are new HIV antiviral drugs on the market? Suimeikai is a three-in-one compound drug whose main ingredients are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. It was approved for marketing in the United States in 2014 and in my country in early 2018. It is indicated for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV).

As a new drug approved for the treatment of AIDS in my country, Suimeikai is the best-selling drug for the treatment of AIDS in my country in the past five years and plays an important role in the field of AIDS treatment.

Suimeikai is a compound drug, that is to say, treatment drugs for different stages of viral infection are integrated into the same tablet. Patients only need to use one drug to achieve the effect of combined medication. One drug is a complete treatment plan with good therapeutic effect and few side effects.

Oral administration of Suimeikai has greatly improved patients' medication compliance and improved their quality of life. The recommended dosage is 1 tablet/time/day. It cannot be used if the patient weighs less than 40KG. In addition, because Trimax is a fixed dose and cannot be adjusted, if one of the active ingredients needs to be discontinued or dose adjusted, separate formulations of abacavir, dolutegravir, or lamivudine can be used. In these cases, physicians should refer to the respective product information for these drugs.

The new AIDS antiviral treatment drug Suimeikai has been launched in more and more countries around the world, bringing new options for the treatment of AIDS patients around the world. We learned that the one currently on the market in India has a relatively low price, about $900 per box. If patients need it, they can consult the medical companion travel service for detailed information.

Recommended related hot articles: /newsDetail/80765.html